-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631.P1.27 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I

Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

O'Hare Thomas, PhD1, Matthew S. Zabriskie2*, Christopher A. Eide3*, Nadeem A. Vellore, PhD2*, Brian J. Druker, MD3 and Michael W Deininger, MD, PhD4

1Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT
2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
4Huntsman Cancer Institute, The University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City, UT

Hongsheng Zhou, MD1,2*, Po Yee Mak, MPhil3*, Hong Mu, MD, PhD4*, Duncan Mak, BSc, MPhil3*, Zhihong Zeng, MD5, Jorge Cortes, MD6, Michael Andreeff, MD, PhD1 and Bing Z Carter1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Hematology, Nanfang Hospital,Southern Medical University, Guangzhou, China
3Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
5Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Hanyang Lin, BSc, MSc1,2, Jonathan Zeng2*, Katharina Rothe, BSc, MSc2,3, Jens Ruschmann, PhD2*, Oleh Petriv, PhD4*, Kieran O'Neill, PhD2*, Tobias Maetzig, PhD2*, David Knapp, BSc1,2*, Ryan R. Brinkman, PhD2,3*, Inanc Birol, PhD3,5*, Donna L. Forrest, MD6, Carl Hansen, PhD4,7*, Connie J. Eaves, PhD1,2,3, R. Keith Humphries, MD, PhD1,2 and Xiaoyan Jiang, MD PhD1,2,3

1Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
3Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
4Center for High-Throughput Biology, University of British Columbia, Vancouver, BC, Canada
5Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, British Columbia Cancer Agency, Vancouver, BC, Canada
6Leukemia/Bone Marrow Transplant Program of BC, British Columbia Cancer Agency, Vancouver, BC, Canada
7Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada

Taehyung Simon Kim1*, Zhaolei Zhang, PhD2*, Marc Tyndel1*, Jae-Sook Ahn, MD, PhD3*, Seunghyun Choi, PhD4*, Hyeoung Joon Kim5, Jeffrey H. Lipton, MD, PhD6 and Dennis Dong Hwan Kim, MD, PhD7

1Department of Computer Science, University of Toronto, Toronto, Canada
2The Donnelly Centre, University of Toronto, Toronto, Canada
3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea
4Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, South Korea
5Chonnam National University,Hwasun Hospital, Hwasun, South Korea
6Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
7Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Isabel Ben Batalla, PhD1,2*, Robert Erdmann, PhD1,2*, Heather Jørgensen, PhD3*, Rebecca Mitchell3*, Thomas Ernst, MD4*, Gunhild von Amsberg, MD1*, Philippe Schafhausen, MD1*, Stephen Rankin, MD3*, Richard E. Clark, Prof MD5*, Steffen Koschmieder, MD6, Alexander Schultze, MD1*, Subir Mitra, MD7*, Peter Vandenberghe, Prof MD, PhD8, Tim H. Brümmendorf, Prof MD6*, Peter Carmeliet, Prof MD, PhD9*, Gudmundur Helgason, PhD10*, Andreas Hochhaus, MD4, Klaus Pantel, Prof MD, PhD2*, Carsten Bokemeyer, MD11*, Tessa L Holyoake, Prof PhD3* and Sonja Loges, MD PhD1,2*

1Department of Hematology and Oncology with Sections BMT and Pneumology, Hubertus Wald Tumorzentrum, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2Institute of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
3Paul O’Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
4Department of Haematology and Medical Oncology, Department of Internal Medicine II, University Hospital Jena, Jena, Germany
5Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
6Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany
7Department of Haematology, Milton Keynes Hospital NHS Foundation Trust, Milton Keynes, United Kingdom
8Human Genetics, KULeuven, Leuven, Belgium
9Laboratory of Angiogenesis and Neurovascular Link, VIB - Katholieke Universiteit Leuven, Vesalius Research Center, LEUVEN, Belgium
10Wolfson Wohl Cancer Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences University of Glasgow, Glasgow, United Kingdom
11Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Santa Errichiello, PhD1*, Simona Caruso2*, Concetta Quintarelli, PhD3*, Biagio De Angelis, PhD4*, Novella Pugliese, MD2*, Roberta Della Pepa2*, Barbara Izzo2*, Luigia Luciano, MD5, Simona Soverini6, Carolina Terragna, PhD7*, Giovanni Martinelli8, Daniela Cilloni, MD, PhD9, Giuseppe Saglio10, Mario Annunziata, MD11*, Giovanni Caocci12*, Luciano Levato, MD13*, Emilio Usala, MD14*, Massimo Breccia, MD15*, Angelo Michele Carella16, Nicola Cascavilla, MD17*, Mariella D'Adda, MD18*, Claudia Galimberti19*, Frank Giles, MD, MB, FRCPI, FRCPath20, Andreas Hochhaus, MD21 and Fabrizio Pane, MD22

1Department of Clinical Medicine and Surgery, University of Naples “Federico II", Naples, Italy
2Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy
3Department of Clinical Medicine and Surgery, University Federico II of Naples, Napoli, Italy
4Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, TX, Italy
5Area Funzionale di Ematologia- II Policlinico, University of Naples “Federico II”, Naples, Italy
6Institute of Hematology, S.Orsola-Malpighi University Hospital, Bologna, Italy
7DIMES - Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology, University of Bologna, Bologna, Italy
8"Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy
9Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy
10University of Turin, Orbassano, Italy
11Hematology, OSPEDALE CARDARELLI, NAPOLI, Italy
12Department of Medical Sciences, University of Cagliari, Cagliari, Italy
13Section of Hematology, A.O. Pugliese-Ciaccio, Catanzaro, Italy
14Hematology Unit, "A.Businco" Hospital, Cagliari, Italy
15Chair of Hematology, "Sapienza" University, Roma, Italy
16Division of Hematology 1, IRCCS A.O.U. San Martino IST, Genova, Italy
17Hematology and BMT Unit, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
18Division of Hematology, A.O. Spedali Civili of Brescia, Brescia, Italy
19NOVARTIS ONCOLOGY COMPANY, ORIGGIO VARESE, Italy
20Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX
21Universitätsklinikum Jena, Jena, Germany
22A.F. di Oncologia Ematologica Diagnostica, Azienda Ospedaliera, Napoli, Italy

Barbara Peter, DVM1,2*, Gregor Eisenwort1,2*, Gabriele Stefanzl2*, Daniela Berger2*, Wolfgang R Sperr, MD1,2*, Johannes Zuber, MD, PhD3* and Peter Valent, MD1,2

1Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
2Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
3Research Institute of Molecular Pathology (IMP), Vienna, Austria

Hu Lei1*, Chunmin Ma1*, Zhen Liu1*, Shenmeng Gao2*, Li Zhou3*, Weiwei Wang1*, Hanzhang Xu1*, Fenghou Gao4*, Yingli Wu5* and Han Liu, PhD6

1Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, shanghai, China
2Wenzhou Medical College, wenzhou, China
3Shanghai Jiao Tong University School of Medicine,ruijin hospital, shanghai, China
4Shanghai Jiao Tong University School of Medicine,Shanghai 1th People's Hospital, shanghai, China
5Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China

Manuela Mancini, PhD1*, Simona Soverini2, Elisa Leo, PhD3*, Fausto Castagnetti, PhD3, Caterina De Benedittis, PhD1*, Gabriele Gugliotta, PhD3*, Gianantonio Rosti, MD3*, Maria Alessandra Santucci, MD3*, Michele Cavo4* and Giovanni Martinelli, MD, PhD5

1"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
2Institute of Hematology, S.Orsola-Malpighi University Hospital, Bologna, Italy
3DIMES - University of Bologna, Bologna, Italy
4Institute of Hematology, Bologna, Italy
5Bologna University School of Medicine, Bologna, Italy

*signifies non-member of ASH